Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Renovorx Inc (RNXT)

Renovorx Inc (RNXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 30,001
  • Shares Outstanding, K 24,001
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,230 K
  • EBIT $ -10 M
  • EBITDA $ -10 M
  • 60-Month Beta 1.11
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.12
  • Number of Estimates 1
  • High Estimate -0.12
  • Low Estimate -0.12
  • Prior Year -0.17
  • Growth Rate Est. (year over year) +29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0800 +15.74%
on 11/21/24
1.5800 -20.89%
on 11/22/24
+0.0600 (+5.04%)
since 11/20/24
3-Month
0.7736 +61.58%
on 10/24/24
1.5800 -20.89%
on 11/22/24
+0.0300 (+2.46%)
since 09/20/24
52-Week
0.7101 +76.03%
on 12/21/23
2.3500 -46.81%
on 12/29/23
+0.5400 (+76.06%)
since 12/20/23

Most Recent Stories

More News
RenovoRx Initiates Patient Enrollment at SCRI Oncology Partners for Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial in Locally Advanced Pancreatic Cancer

RNXT : 1.2500 (+8.70%)
RenovoRx CEO to Host Investor Fireside Chat on Tuesday, December 17th at 4:30 p.m. ET

RNXT : 1.2500 (+8.70%)
RenovoRx Secures Initial Purchase Orders for RenovoCath as Nationwide Demand Grows

RenovoRx reports initial purchase orders for RenovoCath, targeting a multi-million dollar oncology market, with Richard Stark as commercial advisor.Quiver AI SummaryRenovoRx, Inc. has announced a significant...

RNXT : 1.2500 (+8.70%)
RenovoRx Receives First Purchase Orders for its FDA-Cleared RenovoCath® Delivery System

RNXT : 1.2500 (+8.70%)
RenovoRx Expands TIGeR-PaC Study with Northwell Health Cancer Institute to Evaluate Innovative Treatment for Locally Advanced Pancreatic Cancer

Northwell Health Cancer Institute joins TIGeR-PaC study evaluating TAMP therapy for advanced pancreatic cancer. Full enrollment targeted by mid-2025.Quiver AI SummaryRenovoRx, Inc. has announced that the...

RNXT : 1.2500 (+8.70%)
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRx’s Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RNXT : 1.2500 (+8.70%)
RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights

RNXT : 1.2500 (+8.70%)
RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced it joined Pancreatic Cancer Action Network...

RNXT : 1.2500 (+8.70%)
RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of solid tumors, announced that Shaun Bagai, CEO of RenovoRx, will present...

RNXT : 1.2500 (+8.70%)
RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

RenovoRx, Inc . (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company focused on targeted drug-delivery with an initial application in locally advanced pancreatic cancer (LAPC),...

RNXT : 1.2500 (+8.70%)

Business Summary

RenovoRx Inc. is a biopharmaceutical company. It developed a therapy platform targeting difficult-to-treat tumors. RenovoRx Inc. is headquartered in Silicon Valley, California.

See More

Key Turning Points

3rd Resistance Point 1.4300
2nd Resistance Point 1.3500
1st Resistance Point 1.3000
Last Price 1.2500
1st Support Level 1.1700
2nd Support Level 1.0900
3rd Support Level 1.0400

See More

52-Week High 2.3500
Fibonacci 61.8% 1.7236
Fibonacci 50% 1.5300
Fibonacci 38.2% 1.3365
Last Price 1.2500
52-Week Low 0.7101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar